GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (OTCPK:AKBLF) » Definitions » Total Equity

AKBLF (Alk-Abello AS) Total Equity : $754.4 Mil (As of Dec. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Alk-Abello AS Total Equity?

Alk-Abello AS's total equity for the quarter that ended in Dec. 2024 was $754.4 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Alk-Abello AS Total Equity Historical Data

The historical data trend for Alk-Abello AS's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS Total Equity Chart

Alk-Abello AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 515.58 528.80 567.86 650.64 754.41

Alk-Abello AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 650.64 683.69 709.44 757.07 754.41

Alk-Abello AS Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Alk-Abello AS's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=1157.805-403.392
=754.4

Alk-Abello AS's Total Equity for the quarter that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=1157.805-403.392
=754.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alk-Abello AS Total Equity Related Terms

Thank you for viewing the detailed overview of Alk-Abello AS's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Alk-Abello AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (OTCPK:AKBLF) » Definitions » Total Equity
Comparable Companies
OCSE:ZEAL OCSE:BAVA OCSE:GUBRA OCSE:PEG OCSE:GMAB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX SMMT INSM HKSE:02269 BMRN RPRX
Traded in Other Exchanges
ALKBc:UK 0OIR:UK ALK B:Denmark 4AJ0:Germany
Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Website
https://www.alk.net
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.